Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
Statens Serum Institut has developed a new vero-cell culturing technique for the manufacturing of inactivated poliovirus vaccine (IPV). This technique implies that the cultivation of cells and poliovirus is performed in a medium free of materials of animal origin and free of antibiotics. In a double-blind randomised clinical trial, IPV(vero) manufactured by this new technique was compared to conventionally produced IPV(mkc). One hundred and twenty-nine (129) healthy adult volunteers were given booster vaccinations of IPV(vero) (65) or IPV(mkc) (64). Both vaccines were well tolerated and resulted in excellent booster responses. No statistically significant differences were seen between the study groups.
Haastrup
Eva
E
Rigshospitalet, Juliane Marie Center, Paediatric Clinic II 4064, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Thierry-Carstensen
Birgit
B
Jensen
Anders Mørup
AM
Stellfeld
Michael
M
Heilmann
Carsten
C
D000293:Adolescent; D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002522:Chlorocebus aethiops; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects / Q000379:methods*; D008297:Male; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control; D017955:Poliovirus / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D014709:Vero Cells
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated